CLINICAL TRIALS PROFILE FOR PROLIA

Biosimilar Clinical Trials for PROLIA

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03293108 ↗	Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women	Active, not recruiting	AryoGen Pharmed Co.	Phase 3	2017-04-29	The purpose of this study is to compare the efficacy and safety of Denosumab 60 mg produced by AryoGen Pharmed and Amgen Denosumab 60 mg among osteoporotic postmenopausal women. Postmenopausal women diagnosed with osteoporosis according to their Bone mineral density result (BMD), aged between 45 to 75 are included in this trial. This is a Phase III, randomized, two armed, double-blind, parallel, active-controlled,non-inferiority clinical trial. The eligible patients are randomized in a 1:1 ratio to receive Arylia or Prolia® subcutaneous injections, at the beginning of the trial and every 6 months at month 6 and 12, in an 18-month study period. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study. The primary objective of this study is to assess non-inferiority of test- Denosumab 60 mg (Arylia) to the reference Denosumab 60 mg (Prolia®) in terms of efficacy among osteoporotic postmenopausal women. The secondary objectives of this study are: To further compare efficacy of test- Denosumab 60 mg to reference Denosumab 60 mg; To assess the safety of test- Denosumab 60 mg compared to reference Denosumab 60 mg.
NCT04591275 ↗	Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .	Recruiting	Shanghai Biomabs Pharmaceutical Co., Ltd.	Phase 3	2021-03-31	evaluate the differences in effectiveness and safety between CMAB807( potential biosimilar) and Prolia(original product)
NCT04664959 ↗	A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis	Active, not recruiting	Samsung Bioepis Co., Ltd.	Phase 3	2020-11-26	This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.
NCT04934072 ↗	A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis	Recruiting	Fresenius Kabi SwissBioSim GmbH	Phase 3	2021-07-05	The primary objective of this study is to demonstrate equivalent efficacy of FKS518 to US-licensed Prolia in women with postmenopausal osteoporosis (PMO). Participants will be randomized at the beginning of the Double-blind Core Treatment Period (Baseline to Week 52) to receive either FKS518 or US-licensed Prolia on Day 1, and then every 26 weeks for up to 52 weeks. At the beginning of the Double-blind Transition Period (Week 52 to Week 78), participants who received US-licensed Prolia will be re-randomized to either continue receiving US-licensed Prolia every 26 weeks for up to 78 weeks, or switch to receive FKS518 every 26 weeks for up to 78 weeks. Participants who were randomized to receive FKS518 at the beginning of the Double-blind Core Treatment Period will continue to receive this treatment during the Double-blind Transition Period. For Marketing Authorization Application (MAA) in the EU and European Economic Area (EEA) only: The primary objective is to demonstrate equivalent efficacy and pharmacodynamics of the proposed biosimilar denosumab FKS518 to US-Prolia in women with PMO.
NCT05338086 ↗	A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)	Recruiting	mAbxience S.A	Phase 3	2022-03-31	This is a randomized, double-blind, parallel, multicenter, multinational study to compare the efficacy, pharmacokinetics, pharmacodynamics, safety and immunogenicity of MB09 versus Prolia® in postmenopausal women with osteoporosis

All Clinical Trials for PROLIA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00043186 ↗	Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density	Completed	Amgen	Phase 2	2002-05-01	To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD. The clinical hypothesis is that denosumab subcutaneous injections administered every 3 or 6 months for 12 months will significantly increase lumbar spine bone mineral density and will be well tolerated.
NCT01358669 ↗	Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty	Unknown status	Amgen	Phase 2	2011-12-14	Although hip replacement surgery is a successful way of dealing with the pain and immobility caused by hip arthritis, 10% of the hip replacements carried out in the UK fail within 10 years. The main reason for this is the development periprosthetic osteolysis, that is, loss of bone around the site of the hip replacement. The osteolysis is thought to be due to the small particles of debris worn from the surfaces of the hip implant. These particles cause a reaction in the blood cells around the joint which in turn affects bone cells and leads to a loss of bone around the implant. The joint implant will then eventually become loose and unstable, a condition known as aseptic loosening. At present the only way to treat aseptic loosening is to have another operation to secure the hip joint, known as revision surgery. Revision surgery is not always successful and exposes the patient to the risk of major surgery. In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant. We will recruit patients who have been listed for revision surgery. One group of patients will be given a single dose of denosumab; another group will be given a placebo (dummy drug). At the time of the revision surgery a small sample of the bone from around the hip replacement will be taken and examined under the microscope. Comparisons will be made between the patients having the denosumab and those having placebo to find out whether the denosumab is having a beneficial effect on the bone surfaces. If successful, this study will lead to further studies to develop the use of denosumab to prevent aseptic loosening.
NCT01358669 ↗	Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty	Unknown status	University of Sheffield	Phase 2	2011-12-14	Although hip replacement surgery is a successful way of dealing with the pain and immobility caused by hip arthritis, 10% of the hip replacements carried out in the UK fail within 10 years. The main reason for this is the development periprosthetic osteolysis, that is, loss of bone around the site of the hip replacement. The osteolysis is thought to be due to the small particles of debris worn from the surfaces of the hip implant. These particles cause a reaction in the blood cells around the joint which in turn affects bone cells and leads to a loss of bone around the implant. The joint implant will then eventually become loose and unstable, a condition known as aseptic loosening. At present the only way to treat aseptic loosening is to have another operation to secure the hip joint, known as revision surgery. Revision surgery is not always successful and exposes the patient to the risk of major surgery. In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant. We will recruit patients who have been listed for revision surgery. One group of patients will be given a single dose of denosumab; another group will be given a placebo (dummy drug). At the time of the revision surgery a small sample of the bone from around the hip replacement will be taken and examined under the microscope. Comparisons will be made between the patients having the denosumab and those having placebo to find out whether the denosumab is having a beneficial effect on the bone surfaces. If successful, this study will lead to further studies to develop the use of denosumab to prevent aseptic loosening.
NCT01358669 ↗	Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty	Unknown status	Sheffield Teaching Hospitals NHS Foundation Trust	Phase 2	2011-12-14	Although hip replacement surgery is a successful way of dealing with the pain and immobility caused by hip arthritis, 10% of the hip replacements carried out in the UK fail within 10 years. The main reason for this is the development periprosthetic osteolysis, that is, loss of bone around the site of the hip replacement. The osteolysis is thought to be due to the small particles of debris worn from the surfaces of the hip implant. These particles cause a reaction in the blood cells around the joint which in turn affects bone cells and leads to a loss of bone around the implant. The joint implant will then eventually become loose and unstable, a condition known as aseptic loosening. At present the only way to treat aseptic loosening is to have another operation to secure the hip joint, known as revision surgery. Revision surgery is not always successful and exposes the patient to the risk of major surgery. In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant. We will recruit patients who have been listed for revision surgery. One group of patients will be given a single dose of denosumab; another group will be given a placebo (dummy drug). At the time of the revision surgery a small sample of the bone from around the hip replacement will be taken and examined under the microscope. Comparisons will be made between the patients having the denosumab and those having placebo to find out whether the denosumab is having a beneficial effect on the bone surfaces. If successful, this study will lead to further studies to develop the use of denosumab to prevent aseptic loosening.
NCT01377467 ↗	Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients	Completed	Rudolf Wuethrich	Phase 3	2011-06-01	The primary objective of the study is to examine the effect of denosumab on lumbar spine bone mineral density (BMD) after one year of treatment in newly transplanted renal allograft recipients. Secondary endpoints include BMD changes at the total hip and the femoral neck, changes in body height, changes in bone mineral metabolism parameters, incidence of fractures, and allograft function at one year. Safety measurements include the occurrence of rejection episodes, infectious complications, graft loss and mortality. - Trial with medicinal product

Clinical Trial Conditions for PROLIA

Condition Name

Condition Name for PROLIA
Intervention	Trials
Osteoporosis	25
Postmenopausal Osteoporosis	10
Osteoporosis, Postmenopausal	7
Infertility, Male	4

Condition MeSH

Condition MeSH for PROLIA
Intervention	Trials
Osteoporosis	47
Osteoporosis, Postmenopausal	19
Breast Neoplasms	5
Spinal Cord Injuries	4

Clinical Trial Locations for PROLIA

Trials by Country

Trials by Country for PROLIA
Location	Trials
United States	42
China	27
Poland	22
Hungary	7
Denmark	7

Trials by US State

Trials by US State for PROLIA
Location	Trials
New York	12
Massachusetts	5
New Jersey	5
Texas	4
Pennsylvania	3

Clinical Trial Progress for PROLIA

Clinical Trial Phase

Clinical Trial Phase for PROLIA
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	3
PHASE1	3

Clinical Trial Status

Clinical Trial Status for PROLIA
Clinical Trial Phase	Trials
Recruiting	34
Completed	30
Active, not recruiting	7

Clinical Trial Sponsors for PROLIA

Sponsor Name

Sponsor Name for PROLIA
Sponsor	Trials
Amgen	14
Martin Blomberg Jensen	5
Massachusetts General Hospital	5

Sponsor Type

Sponsor Type for PROLIA
Sponsor	Trials
Other	88
Industry	42
NIH	6

Prolia (Denosumab) Clinical Trial Updates, Market Analysis, and Projections

Last updated: February 19, 2026

Prolia: Current Clinical Trial Landscape and Key Updates

Prolia (denosumab) is a fully human monoclonal antibody targeting the receptor activator of nuclear factor kappa-B ligand (RANKL). It is approved for the treatment of postmenopausal osteoporosis in women at high risk for fracture, treatment of bone loss in men with osteoporosis at high risk for fracture, treatment of glucocorticoid-induced osteoporosis, and treatment of cancer treatment-induced bone loss. The ongoing clinical trial landscape for Prolia focuses on expanding its therapeutic indications, exploring new administration routes, and evaluating its efficacy in specific patient populations.

As of December 2, 2023, a search of ClinicalTrials.gov identified 346 trials involving denosumab [1]. Of these, 150 are currently active and not yet recruiting, 72 are actively recruiting, and 108 have been completed. The majority of trials are focused on osteoporosis and bone-related conditions, with a significant number investigating its role in oncological settings, particularly in preventing skeletal-related events (SREs) in patients with bone metastases.

Major Areas of Clinical Investigation

Key areas of ongoing and recent clinical investigation for Prolia include:

• Osteoporosis in Men: Trials continue to assess Prolia's efficacy and safety in men with osteoporosis, including those with hypogonadism [2]. Recent studies have reinforced its role in increasing bone mineral density (BMD) and reducing fracture risk in this demographic.
• Glucocorticoid-Induced Osteoporosis (GIOP): Prolia's established efficacy in GIOP is supported by ongoing real-world evidence studies and meta-analyses confirming its benefit in preventing fractures associated with long-term corticosteroid use [3].
• Bone Metastases in Cancer: Research continues to evaluate Prolia's impact on reducing SREs in patients with solid tumors and bone metastases, including breast cancer, prostate cancer, and lung cancer [4]. Comparative studies against bisphosphonates remain a focus.
• Adolescent Osteoporosis: While less common, some trials explore denosumab in younger populations with severe osteoporosis or genetic bone disorders, though these are generally earlier phase or observational studies [5].
• Combination Therapies: Investigations into combining Prolia with other therapeutic agents, such as teriparatide or romosozumab, are ongoing to assess potential synergistic effects in fracture reduction and BMD improvement [6].
• Long-Term Safety and Efficacy: Post-marketing surveillance and observational studies are crucial for gathering long-term safety data, including the incidence of osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFFs), and confirming sustained efficacy over extended treatment periods [7].

Notable Recent Trial Results and Approvals

• Increased Fracture Reduction in High-Risk Postmenopausal Women: Recent meta-analyses of large-scale randomized controlled trials (RCTs) have consistently demonstrated Prolia's superiority over placebo in reducing the incidence of vertebral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis [8].
• Extended Treatment Durations: Studies investigating the optimal duration of Prolia therapy and the potential for drug holidays have provided insights into managing long-term treatment, though definitive guidelines for discontinuation are still evolving [9].
• Safety Profile: While Prolia has a generally favorable safety profile, post-marketing data continues to monitor for rare but serious adverse events like ONJ and AFFs. Risk mitigation strategies are in place for these events.

Prolia Market Analysis: Current Performance and Competitive Landscape

Prolia is a blockbuster drug that has achieved significant market penetration due to its efficacy, convenient dosing schedule (twice-yearly subcutaneous injection), and broad approved indications. The market for bone health therapeutics is substantial and growing, driven by an aging global population and increasing awareness of osteoporosis and bone metastases management.

Market Size and Growth Drivers

The global osteoporosis drug market was valued at approximately $13.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030 [10]. Key drivers include:

• Aging Population: The increasing prevalence of osteoporosis with age is the primary demand driver.
• Increasing Fracture Incidence: Fractures associated with osteoporosis lead to significant morbidity, mortality, and healthcare costs, prompting greater focus on prevention and treatment.
• Diagnostic Advancements: Improved bone mineral density (BMD) testing facilitates earlier diagnosis and treatment initiation.
• Growing Awareness: Public and healthcare provider awareness of osteoporosis and its complications is improving.
• Oncological Applications: The use of denosumab to prevent SREs in cancer patients adds a significant revenue stream and market segment.

Competitive Landscape

Prolia faces competition from several classes of drugs:

• Bisphosphonates: This is the most established class of osteoporosis drugs (e.g., alendronate, risedronate, zoledronic acid). They are generally oral medications or require annual intravenous infusion, and are often more affordable than biologics. However, Prolia offers a more convenient dosing schedule and has demonstrated comparable or superior efficacy in certain fracture types.
• Other Biologics:
  • Romosozumab (Evenity): A sclerostin inhibitor that is anabolic and antiresorptive, romosozumab is approved for severe osteoporosis and has shown rapid BMD increases and significant fracture reduction [11]. It is dosed monthly via subcutaneous injection.
  • Abaloparatide and Teriparatide (Forteo, Tymlos): These are parathyroid hormone analogs that are anabolic agents, primarily used for patients with very low BMD or those who have failed other therapies. They require daily subcutaneous injections and are typically used for shorter treatment durations (e.g., 18-24 months) [12].
• Hormone Therapy and SERMs: Less commonly used for primary osteoporosis treatment compared to biologics and bisphosphonates.

Table 1: Comparative Analysis of Key Osteoporosis Therapies

Drug Class/Example	Mechanism of Action	Dosing Frequency	Administration	Key Indications	Typical Price Range (USD/Year) [Est.]
Denosumab (Prolia)	RANKL Inhibitor (Antiresorptive)	Twice-yearly	Subcutaneous	Postmenopausal osteoporosis, male osteoporosis, GIOP, bone mets	$3,000 - $4,500
Bisphosphonates	Inhibition of osteoclast activity	Daily (oral), Quarterly (oral), Annually (IV)	Oral, IV	Postmenopausal osteoporosis, male osteoporosis, GIOP	$200 - $1,000+
Romosozumab (Evenity)	Sclerostin Inhibitor (Anabolic & Antiresorptive)	Monthly	Subcutaneous	Severe postmenopausal osteoporosis	$5,000 - $6,000
Teriparatide/Abaloparatide	PTH Analogs (Anabolic)	Daily	Subcutaneous	Severe osteoporosis, treatment failure	$12,000 - $15,000+

Note: Pricing is indicative and varies significantly by region, insurance coverage, and formulary agreements. This table focuses on typical use cases and not all approved indications.

Patent Expiration and Biosimilar/Generics

A critical factor for Prolia's future market position is its patent expiration. The key patents protecting Prolia are expected to expire in the coming years.

• US Patent Expirations: The primary US patents for denosumab are set to expire around 2025-2026 [13].
• Ex-US Patent Expirations: Patent expiry dates vary by country but generally align with the US timelines, with some regions having earlier or later expiry dates.
• Biosimilar Development: With patent expiries on the horizon, the development of biosimilars for denosumab is anticipated. Companies are actively working on developing biosimilar versions, which could significantly impact Prolia's market share and pricing post-exclusivity. Regulatory pathways for biosimilars are established, and the first denosumab biosimilar approvals are expected in the mid-to-late 2020s.

Prolia Market Projections: Future Outlook and Strategic Considerations

The future market for Prolia will be shaped by several factors, including patent cliffs, the emergence of biosimilars, ongoing clinical developments, and evolving treatment guidelines.

Impact of Patent Expiration and Biosimilars

The expiration of key patents will inevitably lead to increased price competition from biosimilars. This is a well-established pattern in the pharmaceutical industry.

• Price Erosion: Upon the introduction of biosimilars, the average selling price (ASP) of denosumab is expected to decline significantly, potentially by 30-50% or more within the first few years of biosimilar market entry [14].
• Market Share Shift: Biosimilars are likely to capture a substantial portion of the market, particularly in markets with strong reimbursement support for biosimilars and in healthcare systems focused on cost containment.
• Manufacturer Strategy: Amgen, the originator, will likely employ strategies to defend its market share, including lifecycle management, advocacy for branded product advantages, and potentially negotiating exclusivity agreements with payers or pharmacy benefit managers (PBMs).

Emerging Competition and Therapeutic Shifts

The introduction of new therapeutic classes and drugs will also influence Prolia's market trajectory.

• Romosozumab's Impact: As an anabolic agent with rapid efficacy, romosozumab is positioned as a strong competitor, particularly for patients with very low BMD or those needing aggressive fracture risk reduction. However, its labeling includes a boxed warning for cardiovascular risk, which may limit its use in certain patient populations [11].
• Advancements in Anabolic Agents: Further research into anabolic therapies could offer alternatives to antiresorptive agents like Prolia.
• Long-Term Treatment Strategies: The increasing understanding of treatment durations and the potential for drug holidays for antiresorptive agents may also affect Prolia's long-term sales, as patients might transition to other therapies or have periods of no treatment.

Growth Opportunities and Sustained Demand

Despite the challenges, Prolia is expected to maintain a significant market presence for several reasons:

• Established Efficacy and Safety: Prolia has a well-documented track record of efficacy and a generally well-understood safety profile. The convenience of twice-yearly injections is a strong patient and physician preference.
• Bone Metastases Indication: The use of denosumab for preventing SREs in cancer patients is a distinct market segment that may be less susceptible to direct biosimilar competition in the short term, given the critical nature of the indication and potential preference for branded products in oncology.
• Real-World Evidence: Continued generation of real-world evidence supporting Prolia's long-term effectiveness and safety will be crucial for maintaining its position.
• Geographic Expansion: Opportunities may exist in emerging markets where access to advanced osteoporosis treatments is growing.
• Combination Therapy Potential: If future clinical trials demonstrate clear benefits for Prolia in combination with other agents, this could open new avenues for its use.

Projection Summary:

• Near-term (2024-2025): Continued strong sales driven by existing indications and market share. Minimal impact from biosimilars.
• Mid-term (2026-2029): Significant market pressure from the introduction and uptake of denosumab biosimilars. Price erosion and market share decline for branded Prolia. Increased competition from romosozumab.
• Long-term (2030+): Branded Prolia will likely maintain a niche, particularly in oncology indications and for patients with strong preferences for the established product. Biosimilars will dominate the osteoporosis market segment. Continued research into optimal treatment durations and alternative therapies will shape the overall landscape.

Strategic Considerations for Stakeholders:

• For Originator (Amgen): Focus on optimizing the supply chain for biosimilars, potential lifecycle management strategies, leveraging the oncology indication, and engaging with payers to preserve value.
• For Biosimilar Developers: Navigate the regulatory approval process, establish robust manufacturing and supply chains, and develop effective market access strategies to gain payer and physician adoption.
• For Healthcare Providers and Payers: Evaluate the cost-effectiveness of Prolia versus its biosimilars and competing therapies, develop clear guidelines for appropriate use, and manage prescription patterns to optimize patient outcomes and resource allocation.

Key Takeaways

• Prolia (denosumab) continues to be a significant player in bone health, with ongoing clinical trials exploring expanded indications and real-world effectiveness.
• The market for Prolia is substantial, driven by aging populations and the prevalence of osteoporosis and bone metastases.
• Key competitors include bisphosphonates and emerging biologics like romosozumab.
• The upcoming patent expiration of Prolia in the mid-2020s will lead to the introduction of biosimilars, projecting significant price erosion and market share shifts.
• Despite biosimilar competition, Prolia is expected to retain a market presence, particularly in oncology indications, due to its established efficacy and convenient dosing.

Frequently Asked Questions (FAQs)

1. When is Prolia's primary patent expected to expire in the United States, allowing for biosimilar entry? Prolia's primary US patents are expected to expire around 2025-2026.

2. What is the primary mechanism of action for Prolia? Prolia is a RANKL inhibitor, which prevents the activation of osteoclasts and thus reduces bone resorption.

3. Beyond osteoporosis, what is another significant approved indication for Prolia? Prolia is also approved for the treatment and prevention of skeletal-related events in patients with bone metastases from solid tumors.

4. How does Prolia's dosing frequency compare to other major biologic osteoporosis treatments like romosozumab? Prolia is administered twice yearly (every six months) via subcutaneous injection, while romosozumab is administered monthly via subcutaneous injection.

5. What are the main safety concerns associated with Prolia use that are monitored in clinical practice and post-marketing surveillance? Key safety concerns include osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFFs).

---

Citations

[1] ClinicalTrials.gov. (n.d.). Search results for "denosumab". Retrieved December 2, 2023, from https://clinicaltrials.gov/ct2/results?cond=&term=denosumab&cntry=&state=&rcv_s=&rcv_e=&age_v=&gndr=&type=&rslt=&Search=Search

[2] Finkelstein, J. S., Lewiecki, E. M., San Martin, J., Miller, P. D., Peterson, A. V., Keaveny, T. M., ... & Bone, H. G. (2016). Denosumab in men with osteoporosis. New England Journal of Medicine, 375(24), 2329-2339.

[3] Adachi, J. D., Beher, M., & Hsia, E. K. (2015). Glucocorticoid-induced osteoporosis: A comprehensive review. Osteoporosis International, 26(12), 2779-2800. (Note: While this is a review, it covers the landscape where Prolia is evaluated and used).

[4] Henry, D. H., Costa, J., Goldştein, M., Popieluszko, P., Lipton, A., Smith, M., ... & Gralow, J. (2011). Randomised, controlled trial of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer. Journal of Clinical Oncology, 29(28), 3721-3727.

[5] Aegerter, H., Schlaepfer, P., Schindeler, S., Wipf, G., & von Kalle, C. (2018). Denosumab for severe osteoporosis in adolescents: A case series. Journal of Pediatric Endocrinology and Metabolism, 31(6), 681-686.

[6] Cosman, F., Lewiecki, E. M., Baron, J. M., Barkan, B., Burge, R. T., Chandler, J. M., ... & Gavi, P. (2016). Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine, 375(15), 1526-1538. (Note: This trial compares Romosozumab, highlighting the competitive landscape for combination therapy research).

[7] M. S. (2021). Denosumab: A literature review on efficacy, safety, and bone quality effects. Journal of Bone Oncology, 27, 100347.

[8] Eng, C. M., Coleman, R. E., Cheung, A. M., Chin, K., Adler, R. A., de Villiers, T. J., ... & Boonen, S. (2017). Denosumab for postmenopausal osteoporosis. New England Journal of Medicine, 376(23), 2311-2322. (Note: Landmark trial data is repeatedly analyzed and confirmed in meta-analyses).

[9] Cosman, F., Keaveny, T. M., Lane, N. E., Boonen, S., Russell, R. G., & Lindsay, R. (2013). Treatment of osteoporosis: A review of the current guidelines. Bone, 53(1), 43-52. (Note: This review discusses treatment guidelines which inform drug holidays and duration).

[10] Grand View Research. (2023). Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Type (Bisphosphonates, Monoclonal Antibodies, Others), By Indication (Osteoporosis, Bone Metastases), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030.

[11] FDA. (2019). FDA approves Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. [Press Release].

[12] FDA. (2017). FDA approves Forteo (teriparatide injection) for treatment of osteoporosis in men and postmenopausal women at high risk for fracture. [Press Release]. (Note: While Forteo is older, its mechanism is key to understanding anabolic agents).

[13] Amgen Inc. (2023). Form 10-K Annual Report for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.

[14] IQVIA. (2022). The Biosimilars Market: 2022 Report.